Gamal Akabani

Gamal Akabani

Associate Professor, Nuclear Engineering

Date of Appointment: 2008

Office: 131D Zachry Engineering Center
Phone: 979/458-1699
Fax: 979/845-6443
E-mail: akabani@ne.tamu.edu

Education

Ph.D., Medical Physics, Texas A&M University, 1990
M.S., Health Physics, Texas A&M University, 1987
B.S., Physics, National Autonomous University of Mexico, 1985.

Courses Taught

NUEN 611: Radiation Detection and Measurement

Hover over the course names to see descriptions. Follow the links to get more details.


Areas of Interest

Basic research: I have demonstrated capacity in the basic medical sciences, biomedical engineering, nuclear medicine imaging, nuclear oncology, radiation Monte Carlo transport, radiation oncology, radiotherapy physics, radiobiology, PK/PD and PBPK modeling, basic immunology, and radiopharmaceutical research. I have used in vivo models using ectopic, orthotopic and metastatic tumor animal models to study the spatiotemporal tumor pathophysiology and effect of therapeutics using MR Microscopy, micro-PET, GFP-based imaging, intra-vital microscopy, FACS, microarray analysis, and immunohistochemical techniques. My research has been focused on the development of diagnostic and therapy strategies for the management and treatment of brain tumors using multi-target and combinatorial drugs, including radiolabeled mAb, immuno-toxins, and small MW anti-invasive compounds, capable of modifying the progression and eradication of invasive tumor cells including cancer stem cells.

Clinical research: I have over ten years of experience in the development and integration of medical systems for the diagnostic and treatment of cancer. My clinical research experience encompasses the use of single photon emission computer tomography (SPECT), positron emission tomography (PET/CT), MRI, pharmacokinetic modeling, radiation dosimetry, small-scale dosimetry, and morphological microdosimetry of gamma, beta and alpha particle emitting radiolabeled mAbs and compounds for the treatment of cancer using systemic and loco-regional delivery routes. Furthermore, I have extensive experience in the development and execution of clinical trials with radiolabeled monoclonal antibodies for the treatment of Non-Hodgkin’s lymphoma and brain tumors. Of relevance, I carried out the multi-center phase I, II clinical trials of 131I-labeled 81C6 mAb for the therapy of brain tumors, phase I, II and III clinical trials of 131I-labeled tositumomab mAb (BEXXAR) (Anti-CD20) for the treatment of NHL, and phase I clinical trial of the alpha particle emitting 211At-labeled anti-tenascin chimeric 81C6 mAb for the treatment of recurrent brain tumors.

Curriculum Vita: Click Here to View


Recent Publications

Journal Articles:

  1. J. H. Sampson, G. Akabani, G. E. Archer, M. S. Berger, R. E. Coleman, A. H. Friedman, H. S. Friedman, K. Greer, J. E. Herndon, II, S. Kunwar, R. E. McLendon, A. Paolino, N. A. Petry, J. M. Provenzale, D. A. Reardon, T. Z. Wong, M. R. Zalutsky, I. Pastan, and D. D. Bigner, "Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors," Neuro-Oncology 10(3), 320-9, 2008.
  2. D. A. Reardon, M. R. Zalutsky, G. Akabani, R. E. Coleman, A. H. Friedman, J. E. Herndon, II, R. E. McLendon, C. N. Pegram, J. A. Quinn, J. N. Rich, J. J. Vredenburgh, A. Desjardins, S. Guruangan, S. Boulton, R. H. Raynor, J. M. Dowell, T. Z. Wong, X-G Zhao, H. S. Friedman, and D. D. Bigner , "A pilot study: 131I-Antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost," Neuro-Oncology 10(2), 182-189, 2008.
  3. J. H. Sampson, G. Akabani, G. E. Archer, M. S. Berger, R. E. Coleman, A. H. Friedman, H. S. Friedman, K. Greer, J. E. Herndon, S. Kunwar, R. E. McLendon, A. Paolino, N. A. Petry, J. M. Provenzale, D. A. Reardon, T. Z. Wong, M. R. Zalutsky, I. Pastan, and D. D. Bigner, "Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors," Neuro-Oncology 10(3), 320-329, 2008.
  4. M. R. Zalutsky, D. A. Reardon, G. Akabani, R. E. Coleman, A. H. Friedman, H. S. Friedman, J. E. Herndon, II, R. E. McLendon, C. N. Pegram, J. M. Provenzale, J. A. Quinn, J. N. Rich, J. J. redenburgh, A. Desjardins, S. Guruangan, S. Sathornsumettee, J. H. Sampson, T. Z. Wong, X-G Zhao, and D. D. Bigner., "Clinical Experience with α-Emitting Astatine-211: Treatment of Recurrent Brain Tumor Patients with 211At-labeled Chimeric 81C6 Anti-Tenascin Monoclonal Antibody 81C6," Journal of Nuclear Medicine 49(1), 30-38, 2007.
  5. R. E. McLendon, G. Akabani, H. S. Friedman, D. A. Reardon, L. Cleveland, I. Cokgor, J. E. Herndon II, C. Wikstrand, S. T. Boulton, A. H. Friedman, D. D. Bigner, and M. R. Zalutsky., "Tumor Resection Cavity Administered Iodine-131-Labeled Antitenascin 81C6 Radioimmunotherapy in Patients with Malignant Glioma: Neuropathology Aspects," Nuclear Medicine and Biology 34(4), 405-13, 2007.
  6. S. Vemulapalli, S. D. Metzler, G. Akabani, N. A. Petry, N. J. Niehaus, X. Liu, N. H. Patil, K. L. Greer, R. J. Jaszczak, R. E. Coleman, C. Dong, P.J. Goldschmidt-Clermont, and B. B. Chin, "Cell Therapy in Murine Atherosclerosis: In Vivo Imaging with High-Resolution Helical SPECT," Radiology 242(1), 198-207, 2007.